Bristol-Myers Squibb Co (BMY)

Industry Drug Manufacturers - General


This stock can be held in an Investment ISA and an Investment Account
Sell

$54.66

Buy

$54.82

arrow-down$-0.57 (-1.03%)

Prices updated at 08 Nov 2024, 00:59 EST
| Prices minimum 15 mins delay
|
Prices in USD

Bristol-Myers Squibb Co is engaged in discovery, development, licensing, manufacturing, marketing, distribution and sale of biopharmaceuticals products. The company operates in one segment that is Biopharmaceuticals.

Income statement

20222023
46,159m45,006m
36,022m34,313m
9,104m8,195m
19.7218.21
6,327m8,025m
19,221m19,366m
Sales, General and administrative7,814m7,772m
Interest expenses1,232m1,166m
Provision for income taxes1,368m400m
Operating expenses26,918m26,118m
Income before taxes7,713m8,440m
Net income available to common shareholders6,327m8,025m
2.973.88
Net interest income-1,232m-1,166m
Advertising and promotion--
Net investment income, net--
Realised capital gains (losses), net--
Total benefits, claims and expenses--
Earnings per share (diluted)2.953.86
Free cash flow per share5.8625.5655
Book value/share15.745114.3483
Debt equity ratio1.1692151.297418

Balance sheet

20222023
Current assets27,273m31,770m
Current liabilities21,890m22,262m
Total capital66,117m66,083m
Total debt40,717m41,464m
Total equity31,061m29,430m
Total non current liabilities--
Loans35,056m36,653m
Total assets96,820m95,159m
Total liabilities--
Cash and cash equivalents9,123m11,464m
Common stock2,075m2,021m

Cash flow

20222023
Cash at beginning of period14,316m9,325m
Cash dividends paid-4,634m-4,744m
11,948m12,651m
Investments (gains) losses-1,062m-2,295m
9,325m11,519m
Net income--
13,066m13,860m
-1,118m-1,209m
The figures shown in the tables are quoted in the currency of the stock selected.
Please note that past performance is not a reliable indicator of future returns. Please use the interactive graph for benchmark comparison.

Important Information

Please note the value of investments can go down as well as up so you may get back less than you invested. This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to an authorised financial adviser. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and(3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information.
© Copyright 2024 Morningstar. All rights reserved.